RECRUITING

Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases

Talk to us

Conditions

Clinical Stage IVB Gastric Cancer AJCC v8Metastatic Gastric AdenocarcinomaMetastatic Malignant Neoplasm in the Peritoneum

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This phase I trial tests the safety, side effects and best dose of nab-paclitaxel pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in combination with second-line chemotherapy, paclitaxel and ramucirumab, and tests how well they work in treating stomach cancer that has spread from where it first started to the tissue that lines the abdominal wall and organs (peritoneal metastases). Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. PIPAC delivers chemotherapy, such as nab-paclitaxel, that has been turned into a fine mist (aerosolized) at a high pressure directly into the abdominal cavity. Aerosolized chemotherapy delivered directly into the peritoneal space has been shown to deliver higher drug concentrations to the tumor. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving nab-paclitaxel PIPAC in combination with paclitaxel and ramucirumab may be safe, tolerable, and/or effective in treating gastric cancer patients with peritoneal metastases.

Official Title

Phase 1 Trial of Nab-Paclitaxel PIPAC (Pressurized Intraperitoneal Aerosolized Chemotherapy) Given in Combination With Second-Line Therapy for Gastric Cancer With Peritoneal Metastases

Quick Facts

Study Start:2025-10-17
Study Completion:2029-01-14
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06675136

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients must have failed first-line systemic therapy (fluorouracil, leucovorin calcium, oxaliplatin \[FOLFOX\] with or without immunotherapy, or other fluoropyrimidine and platinum-based therapy)
  2. * Prior immunotherapy allowed
  3. * Up to 4 cycles of second-line therapy allowed if no progression is documented
  4. * Documented informed consent of the participant and/or legally authorized representative
  5. * Assent, when appropriate, will be obtained per institutional guidelines
  6. * Agreement to allow the use of archival tissue from diagnostic tumor biopsies
  7. * If unavailable, exceptions may be granted with study principal investigator (PI) approval
  8. * Age: ≥ 18 years
  9. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  10. * Histologically or cytologically confirmed gastric adenocarcinoma
  11. * Visible peritoneal metastatic disease on cross-sectional imaging or diagnostic laparoscopy (does not have to be measurable by RECIST 1.1)
  12. * Fully recovered from acute toxic effects (except alopecia, hearing loss, or non-clinically significant laboratory abnormalities) ≤ grade 1 of prior anti-cancer therapy
  13. * The patient's urinary protein is ≤ 1+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates proteinuria ≥ 2+, then a 24-hour urine must be collected and must demonstrate \< 1000mg protein in 24 hours
  14. * Complete medical history and physical exam (within 28 days prior to day 1 of protocol therapy)
  15. * Absolute neutrophil count (ANC) ≥ 1,500/mcL (within 28 days prior to day 1 of protocol therapy)
  16. * Platelets ≥ 100,000/mcL (within 28 days prior to day 1 of protocol therapy)
  17. * Hemoglobin ≥ 8 g/dL (within 28 days prior to day 1 of protocol therapy)
  18. * Serum albumin ≥ 2.8 g/dL (within 28 days prior to day 1 of protocol therapy)
  19. * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless has Gilbert's disease, then direct bilirubin \< 1.5 mg/dL) (within 28 days prior to day 1 of protocol therapy)
  20. * Aspartate aminotransferase (AST) ≤ 5 x ULN (within 28 days prior to day 1 of protocol therapy)
  21. * Alanine aminotransferase (ALT) ≤ 5 x ULN (within 28 days prior to day 1 of protocol therapy)
  22. * International normalized ratio (INR) ≤ 1.5 x ULN (within 28 days prior to day 1 of protocol therapy)
  23. * Prothrombin time (PT) ≤ 1.5 x ULN (within 28 days prior to day 1 of protocol therapy)
  24. * Partial thromboplastin time (PTT) ≤ 1.5 x ULN (within 28 days prior to day 1 of protocol therapy)
  25. * Calculated creatinine clearance of ≥ 45 mL/min per 24 hour urine test or the Cockcroft-Gault formula (within 28 days prior to day 1 of protocol therapy)
  26. * Seronegative for HIV antigen (Ag)/antibody (Ab) combo (within 28 days prior to day 1 of protocol therapy)
  27. * If seropositive, patient may be eligible if they are stable on antiretroviral therapy, have a CD4 T cell count ≥ 200/µL, and have an undetectable viral load
  28. * Documented virology status of hepatitis, confirmed by hepatitis B virus (HBV) and hepatitis C virus (HCV) tests (within 28 days prior to day 1 of protocol therapy)
  29. * For patients with active HBV, HBV deoxyribonucleic acid (DNA) \< 500 IU/mL during screening, initiation of anti-HBV treatment at least 14 days prior to day 1 of cycle 1, and willingness to continue anti-HBV treatment during the study (per standard of care)
  30. * If seropositive for HCV, nucleic acid quantification must be performed. Viral load must be undetectable
  31. * WOMEN OF CHILDBEARING POTENTIAL (WOCBP): Negative urine or serum pregnancy test (within 28 days prior to day 1 of protocol therapy)
  32. * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  33. * Agreement by females and males of childbearing potential to use an effective method of birth control (e.g., licensed hormonal/barrier methods or surgery intended to prevent pregnancy \[or with a side effect of pregnancy prevention\]) or abstain from heterosexual activity for the course of the study through at least 14 months after the last dose of protocol therapy.
  34. * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)
  1. * Intolerance to taxanes
  2. * Bowel obstruction requiring exclusive total parenteral nutrition
  3. * Any history of, or current, brain or subdural metastases
  4. * Life expectancy \< 3 months
  5. * Treatment with therapeutic oral or IV antibiotics within 14 days prior to day 1 cycle 1 of treatment
  6. * Patients receiving prophylactic antibiotics are eligible, provided the signs of active infection have resolved
  7. * Any prior malignancy except adequately treated basal or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for two years
  8. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents (taxanes, etc.)
  9. * Clinically significant uncontrolled illness such as uncontrolled hypertension (HTN)
  10. * History of arterial thromboembolic events such as myocardial infarction (MI), cerebrovascular accident (CVA)
  11. * History of gastrointestinal (GI) perforation
  12. * FEMALES ONLY: Pregnant or breastfeeding
  13. * Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  14. * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Contacts and Locations

Principal Investigator

Yanghee Woo
PRINCIPAL_INVESTIGATOR
City of Hope Medical Center

Study Locations (Sites)

City of Hope Medical Center
Duarte, California, 91010
United States

Collaborators and Investigators

Sponsor: City of Hope Medical Center

  • Yanghee Woo, PRINCIPAL_INVESTIGATOR, City of Hope Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-10-17
Study Completion Date2029-01-14

Study Record Updates

Study Start Date2025-10-17
Study Completion Date2029-01-14

Terms related to this study

Additional Relevant MeSH Terms

  • Clinical Stage IVB Gastric Cancer AJCC v8
  • Metastatic Gastric Adenocarcinoma
  • Metastatic Malignant Neoplasm in the Peritoneum